Talidomid - nowe znaczenie terapeutyczne teratogennego leku = Thalidomide – new therapeutic value of teratogenic drug

Agnieszka Surowiec, Łukasz Wołowiec, Justyna Surowiec, Małgorzata Wołowiec, Bartosz Kochański, Krystian Kałużny, Anna Plaskiewicz, Alicja Krakowska, Walery Zukow

Abstract


Surowiec Agnieszka, Wołowiec Łukasz, Surowiec Justyna, Wołowiec Małgorzata, Kochański Bartosz, Kałużny Krystian, Plaskiewicz Anna, Krakowska Alicja, Zukow Walery. Talidomid - nowe znaczenie terapeutyczne teratogennego leku = Thalidomide – new therapeutic value of teratogenic drug. Journal of Education, Health and Sport. 2015;5(6):341-354. ISSN 2391-8306. DOI 10.5281/zenodo.18712

http://ojs.ukw.edu.pl/index.php/johs/article/view/2015%3B5%286%29%3A341-354

https://pbn.nauka.gov.pl/works/567418

http://dx.doi.org/10.5281/zenodo.18712

Formerly Journal of Health Sciences. ISSN 1429-9623 / 2300-665X. Archives 2011 – 2014 http://journal.rsw.edu.pl/index.php/JHS/issue/archive

 

Deklaracja.

Specyfika i zawartość merytoryczna czasopisma nie ulega zmianie.

Zgodnie z informacją MNiSW z dnia 2 czerwca 2014 r., że w roku 2014 nie będzie przeprowadzana ocena czasopism naukowych; czasopismo o zmienionym tytule otrzymuje tyle samo punktów co na wykazie czasopism naukowych z dnia 31 grudnia 2014 r.

The journal has had 5 points in Ministry of Science and Higher Education of Poland parametric evaluation. Part B item 1089. (31.12.2014).

© The Author (s) 2015;

This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland and Radom University in Radom, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,

provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License

(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial

use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 21.04.2015. Revised 28.05.2015. Accepted: 16.06.2015.

 

Talidomid - nowe znaczenie terapeutyczne teratogennego leku

Thalidomide – new therapeutic value of teratogenic drug

 

Agnieszka Surowiec1, Łukasz Wołowiec1, Justyna Surowiec2, Małgorzata Wołowiec3, Bartosz Kochański4, Krystian Kałużny4, Anna Plaskiewicz4, Alicja Krakowska4, Walery Zukow5

 

1Studenckie Koło Naukowe Diagnostyki i Terapii Niewydolności Serca, II Katedra Kardiologii, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu

2Studenckie Koło Naukowe anatomii topograficznej człowieka, Katedra anatomii człowieka, Międzynarodowy Uniwersytet Medyczny w Ivano- Frankivsku

3Koło Naukowe Psychologii Zarządzania, Katedra Nauk Społecznych, Katolicki Uniwersytet Lubelski Jana Pawła II

4Katedra i Klinika Rehabilitacji, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu;

5Instytut Kultury Fizycznej, Wydział Kultury Fizycznej, Zdrowia i Turystyki, Uniwersytet Kazimierza Wielkiego w Bydgoszczy

 

Streszczenie

Szpiczak mnogi (MM) jest drugim co do częstości nowotworem hematologicznym. Interakcje między komórkami szpiczaka i mikrośrodowiska są niezbędne dla przetrwania komórek MM. W szpiczaku mnogim, występują zaburzenia dotyczące komórek plazmatycznych (komórek szpiczaka), gromadzących się w szpiku kostnym wielu kości organizmu. W ciągu ostatniej dekady nastąpił znaczny postęp wiedzy o biologii szpiczaka mnogiego (MM) i jego leczeniu. Mimo tej znacznej poprawy, MM wciąż pozostaje chorobą nieuleczalną i skłania do poszukiwania dodatkowych opcji terapeutycznych.

Badania kliniczne nad talidomidem stosowanym zarówno w monoterapii jak i w skojarzeniu z innymi lekami, potwierdziły korzyści zarówno w nawrotowym i opornym na leczenie szpiczaku mnogim. Talidomid daje korzystną odpowiedź u chorych na szpiczaka mnogiego stosowany w monoterapii, a ponadto działa synergistycznie z kortykosteroidami i innymi chemioterapeutykami. Wywoływana przez talidomid neuropatia obwodowa jest zwykle symetryczna i charakteryzuje się bolesnymi parestezjami rąk i stóp z często towarzyszącą utratą czucia w stopach. Badania nad mechanizmami działania talidomidu prowadzi do lepszego zrozumienia celów terapeutycznych na poziomie molekularnym.

 

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy. Interactions between myeloma cells and the microenvironment are essential for MM cell survival. In multiple myeloma, abnormal plasma cells (myeloma cells) build up in the bone marrow and form tumors in many bones of the body. Major advances have occurred in our understanding of the biology of multiple myeloma and in its treatment in the past decade. Despite this significant improvement in the overall outcome, multiple myeloma remains incurable in the majority of patients, prompting a continued search for additional therapeutic options.

Clinical trials both as a single agent and in combination have confirmed benefit in relapsed and refractory disease. Thalidomide is being investigated currently in a number of clinical trials for cancer. Thalidomide causes responses of myeloma patients as a single agent, and acts synergistically with corticosteroids and chemotherapy. Thalidomide-induced peripheral neuropathy is typically symmetrical, and is characterized by painful paresthesia of the hands and feet, often accompanied by sensory loss in the feet. Research on thalidomide mechanisms of action is leading to a better understanding of molecular targets.

 

Słowa kluczowe: Talidomid, Szpiczak mnogi, MM.

 

Key words: Talidomid, Multiple myeloma, MM.


Keywords


Talidomid, Szpiczak mnogi, MM, Talidomid, Multiple myeloma, MM.

Full Text:

PDF (Polski)

References


Durie BM, Kyle RA i wsp. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J, 2003; 4: 379–398.

Durie BGM, Jacobson J i wsp. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. Jurnal of Clinical Oncology, 2004; 22: 1857–1863.

Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer, 1975; 36: 842–854.

Palumbo A, Anderson K. Multiple myeloma. The New England Jurnal of Medicine, 2011; 364: 1046–1060.

Angtuaco EJC i wsp. Multiple myeloma: clinical review and diagnostic imaging. Radiology, 2004; 231:11-23.

Greek R, Shanks N, Rice MJ. The History and Implications of Testing Thalidomide on Animals. The Journal of Philosophy, Science & Law, 2011; 11. www.miami.edu/ethics/jpsl

HISTORY ANIMAL

Moreau P, San Miguel J, Ludwig H, I wsp. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013;24: 133–137.

Krajowy Rejestr Nowotworów. Polska 2012; http://onkologia.org.pl/raporty/; dostęp 27.05.2016r.

Palumbo A, San Miguel J, Sonneveld P i wsp. Lenalidomide: A new therapy for multiple myelomaReview. Cancer Treatment Reviews, 2008, 34, 283-291.

García-Sanz R, Mateos M V, San Miguel J F. Mieloma multiple. Medicina Clínic, 2007; 129: 104-115.

Fonseca R, San Miguel J. Prognostic Factors and Staging in Multiple Myeloma. Hematology/Oncology Clinics of North America, 2007; 21: 1115-1140.

Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma.Br J Haematol, 2012; 159: 499–513.

Morgan G J, Gregory W M, Davies F E i wsp. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood, 2012; 119: 7–15.

Fernanda Sales LV, De Oliveira MZ, Vieira Sanseverino MT i wsp. Pharmacoepidemiology and thalidomide embryopathy surveillance in Brazil. Reproductive Toxicology, 2015; 53: 63-67.

Hui JY, Hoffmann M, Kumar G. Embryo–fetal exposure and developmental outcome of thalidomide following oral and intravaginal administration to pregnant rabbits., 2014; 48: 115-123.

Vianna FSL, Fraga LR, Tovo-Rodrigues L, Tagliani-Ribeiro A i wsp. Polymorphisms in the endothelial nitric oxide synthase gene in thalidomide embryopathy. Reproductive Toxicology, 2013; 35: 89-92.

Macpherson GR, Franks M, Tomoaia-Cotisel A i wsp. Current status of thalidomide and its role in the treatment of metastatic prostate cancer, 2003; 46: 49-57.

Davis M, Lasheen W, Walsh D i wsp. A Phase II Dose Titration Study of Thalidomide for Cancer-Associated Anorexia. Journal of Pain and Symptom Management, 2012; 43: 78-86.

Chen M., Doherty S. D., Hsu S. Innovative Uses of Thalidomide. Dermatologic Clinics, 2010; 28: 577-586.

Stephens T. D. Reinventing Thalidomide. Chemistry in Britain, 2001;37: 38-40.

Ng S. S. W., Brown M., Figg W. D. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomedicine & Pharmacotherapy, 2002; 56:194-199.

Yasui K., Kobayashi N., Yamazaki T. I wsp. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Current Pharmaceutical Design, 2005; 11: 395-401.

Shannon E. J., Morales M. J., Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology, 1997; 35: 203-122.

Tavares J. L., Wangoo A., Dilworth P. I wsp. Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages. Respiratory Medicine, 1997; 91: 31-39.

Jerram T. Hypnotics and sedatives. Side Effects of Drugs Annual, 1986; 10:40-48.

Meierhofer Ch., Wiedermann Ch. New insights into the pharmcological and toxicological effects of thalidomide. Current Opinion in Drug Discovery & Development, 2003; 6: 92-99.

Okafor M. Thalidomide for Erythema Nodosum Leprosum and Other Applications. Pharmacotherapy, 2003; 23: 481-493.

Rajkumar S.V. Multiple myeloma. American Jurnal of Hematology, 2012; 87: 78–88.

Lokhorst H. M., Van der Holt B., Zweegman S., I wsp. Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood., 2010; 115: 1113–1120.

Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays, 2009; 31: 1327-36.

Sjöström H, Nilsson R: Thalidomide and the power of the drug companies. Penguin,1972:310.http://books.google.pl/books?id=BNNMAgAAQBAJ&pg=PA310&lpg=PA310&dq#v=onepage&q&f=false.

Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS Journal, 2005; 7: 14-19.

Rokicka-Piotrowicz M. Talidomid w leczeniu szpiczaka mnogiego. Współczesna Onkologia, 2001, 5; 161-164.

Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut., 2002; 50: 196-200.

Mitsiades N, Mitsiades CS, Poulaki V i wsp. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002; 99: 4525–4530.

Chauhan D, Pandey P, Ogata A i wsp. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 1997; 15: 837–843.

Keifer JA, Guttridge DC, Ashburner BP i wsp.Inhibition of NF−κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem., 2001; 276: 22382–22387.

Davies FE, Raje N, Hideshima T I wsp. Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 2001; 98: 210–216.

Kalter H. Teratology in the 20th century Environmental causes of congenital malformations in humans and how they were established. Teratology in the Twentieth Century, 2003; 131-282.

Therapontos C, Erskine L, Gardner ERi wsp. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy of Sciences of United States of America, 2009; 106(21): 8573-8.

Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS Journal, 2005; 7: 14-19.

Dimopoulos MA, Zervas K, Kouvatseas G I wsp. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol., 2001; 12: 991–995.

Palumbo A., Larocca A, P. Falco, et al. Lenalidomide, melphalan, prednisone and Thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010; 24: 1037–1042.

Pineda-Roman M, Zangari M, Van Rhee F I wsp. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, 2008; 22: 1419–1427.

Terpos E, Kastritis E, Roussou M I wsp. The combination of bortezomib, melphalan dexamethason and intermittent thalidomide is an effective regiment for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angionesis. Leukemia,2008; 22: 2247–2256.

Dmoszyńska A, Walter-Croneck A, Usnarska-Zubkiewicz L i wsp. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015. Acta Haematologica Polonica, 2015;46: 159-211.

Ludwig H, Adam Z, Tóthová E i wsp.Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with multiple myeloma. Haematologica., 2010; 95: 1548–1554.

Offidani M, Corvatta L, Polloni C I wsp. Thalidomide-dexamethason versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br. J. Haematol., 2008; 144: 653–659.

Kagoya Y, Nannya Y, Kurokawa M. Thalidomide maintenance therapy for patients with multiple myeloma: Metaanalysis. Leuk Res.2012; 36: 1016–1021.

Jabłoński M., Furmaga-Jabłońska W. Wydolność mechaniczna szkiletu – czynniki wpływające na wytrzymałość kości. Choroby metaboliczne kości pod red. Badurski J. Wydawnictwo Medyczne Borgis. Warszawa,2005; 61-73.

Corthals SL, Kuiper R, Johnson DC i wsp. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica,2011; 96: 728–1732.

Johnson DC, Corthals SL, Walker BA i wsp. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol., 2011; 29: 797–804.

Dimopoulos MA, Mateos MV, Richardson PG i wsp. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol, 2011; 86: 23–31.

Ibanez CF, Simi A. p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci,2012; 35: 431–440.

Delforge M, Bladé J, Dimopoulos MA i wsp. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol., 2010; 11: 1086.

Richardson PG, Xie W, Mitsiades C i wsp.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol., 2009; 27: 3518.

Johnson DC: Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients. Blood, 2008; 112: Abstract 1675.

Mileshkin L, Stark R, Day B I wsp. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J. Clin. Oncol., 2006; 24: 4507.

Brunton L, Parker K, Blumenthal D, Buxton I: Podręcznik farmakologii i terapii Goodmana i Gilmana. Wydawnictwo Czelej. Lublin, 2010; 595-596.

Ehrenpreis ED, Kane SV, Cohen LB I wsp. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial. Gastroenterology, 1999; 117: 1271-1277.

Powrie F, Leach MW, Mauze S I wsp. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45Rbhi CD4+ cells. Immunity, 1994; 1: 553–562.

Neurath MF, Fuss I, Pasparakis M I wsp. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol, 1997; 27: 1743–1750.

Wolkenstein P, Latarjet J, Roujeau JC I wsp. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet, 1998; 352: 1586–1589.

Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med, 2000; 108: 487–495.

Huang F, Wei JCC, Breban M. Thalidomide in ankylosing spondylitis. Clin. Exp. Rheumatol., 2002; 20: 158-161.

Shek LPC, Lim CLC. Thalidomide in Behçet’s disease. Biomedicine & Pharmacotherapy, 2002; 56: 31-35.

Chen M, Doherty SD, Hsu S. Innovative Uses of Thalidomide. Dermatologic Clinics, 2010; 28: 577-586.

Gori A, Franzetti F, Marchetti G i wsp. Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection. Clin Infect Dis, 1998; 26: 184–185.

Singhal S, Mehta J. Thalidomide in cancer. Biomedicine & Pharmacotherapy, 2002; 56: 4-12.

Chen M, Doherty SD, Hsu S. Innovative Uses of Thalidomide. Dermatologic Clinics, 2010; 28: 577-586.

Matthews SJ, McCoy PCh. Thalidomide: A review of approved and investigational uses. Clinical Therapeutics, 2003; 25: 342-395.

Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case. J Am Acad Dermatol, 1998 ;39: 835–838.

Bradley D. Thalidomide reduces steroid dose for Crohn’s patients. Pharmaceutical Science & Technology Today, 2000; 3: 49.


Refbacks

  • There are currently no refbacks.




Copyright (c)



Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

Journal Language(s): English 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2  www.ukw.edu.pl Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy http://ojs.ukw.edu.pl/index.php/johs  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase Index.com.

Website: www.infobaseindex.com

Universal Impact Factor 1.78 for year 2012. (http://www.uifactor.org/AppliedJournals.aspx)

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)